OUP user menu

Journal of Crohn's and Colitis: 9 (3)


Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium


Published on behalf of

Intensification of infliximab therapy in Crohn's disease: Efficacy and safety

M. Chaparro , P. Martínez-Montiel , M. Van Domselaar , F. Bermejo , J.L. Pérez-Calle , B. Casis , A. López-San Román , A. Algaba , J. Maté , J.P. Gisbert
DOI: http://dx.doi.org/10.1016/j.crohns.2011.07.005 62-67 First published online: 1 February 2012


Introduction: The response of Crohn's disease (CD) to infliximab is initially good, although a loss of efficacy is observed over time. Dose escalation has been recommended in such cases.

Aims: To study the response to an intensified infliximab regimen in patients with CD; and to evaluate the adverse effects associated with intensification of therapy and identify predictors of loss of response.

Methods: We performed a retrospective multicenter survey of all patients with CD who had been treated with at least the 3 induction doses of standard infliximab therapy, and for whom treatment had to be intensified due to loss of response. We analyzed the efficacy of the intensified regimen.

Results: Thirty-three patients were included. After the first intensification dose, 79% of patients had a clinical response (33.5% complete response, 45.5% partial response). In the long term, 83%, 69%, 47%, and 29% of patients who had an initial response to the intensification maintained the response at 6, 12, 18, and 36 months, respectively. The loss of efficacy after escalation was 43% per patient-year of follow-up. One patient had an infusion reaction after 36 doses. One patient developed a herpes zoster infection.

Conclusions: A high proportion of patients whose dose of infliximab is increased due to loss of efficacy respond initially. However, nearly half lose the response after one year. The safety profile of an intensified infliximab regimen is good.

  • Infliximab
  • Intensification
  • Dose escalation
  • Loss of response
  • Crohn's disease
  • Abbreviations:
    Crohn's disease
    tumor necrosis factor
    standard deviation
    interquartile range
    confidence interval
    hazard ratio
    Harvey–Bradshaw index
  • View Full Text

    Dear ECCO Member

    You now have access to JCC (Journal of Crohn’s and Colitis) and its Supplements as part of your ECCO Membership. Enjoy!
    In case you wish to set up table of contents alerts (eToCs), latest article alerts (Advance Access alerts) or other search alerts, you will need to register for an Oxford Journals MyAccount here.

    Log in through your institution